Summary of Study ST003107

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001775. The data can be accessed directly via it's Project DOI: http://dx.doi.org/10.21228/M88M6V This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST003107
Study TitleCharacterization of metabolic changes upon FGFR inhibition in ICC13-7 Xenograft
Study SummaryGenomic alterations that activate FGFR2 are common in intrahepatic cholangiocarcinoma (ICC) and confer sensitivity to treatment with FGFR inhibitors. However, the depth and duration of responses are often limited. Here, we conducted integrative transcriptomic and metabolomic analysis of patient-derived models to define the pathways that fuel tumor growth downstream of oncogenic FGFR2 signaling in ICC and to uncover compensatory mechanisms associated with pathway inhibition. We find FGFR2-mediated activation of NF-B maintains a highly glycolytic phenotype. Conversely, FGFR inhibition blocks glucose uptake and glycolysis while inciting a series of adaptive changes, including switching fuel source utilization to favor fatty acid oxidation and increasing mitochondrial fusion and autophagy. Accordingly, FGFR inhibitor efficacy is potentiated by combined mitochondrial targeting, an effect enhanced in xenograft models by intermittent fasting. Thus, we show that oncogenic FGFR2 signaling drives NF-B-dependent glycolysis in ICC and that metabolic reprogramming in response to FGFR inhibition confers new targetable vulnerabilities.
Institute
Massachusetts General Hospital
Last NameZhen
First NameYuanli
Address185 cambridge street, room 4100
Emailyzhen1@mgh.harvard.edu
Phone4698792279
Submit Date2024-01-17
Raw Data AvailableYes
Raw Data File Type(s)raw(Thermo)
Analysis Type DetailLC-MS
Release Date2024-03-20
Release Version1
Yuanli Zhen Yuanli Zhen
http://dx.doi.org/10.21228/M88M6V
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Factors:

Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)

mb_sample_id local_sample_id treatment Sample source
SA333658SUB13746p4_SPL08Pemigatinib ICC13-7 Xenograft
SA333659SUB13746p4_SPL07Pemigatinib ICC13-7 Xenograft
SA333660SUB13746p4_SPL06Pemigatinib ICC13-7 Xenograft
SA333661SUB13746p4_SPL03Vehicle ICC13-7 Xenograft
SA333662SUB13746p4_SPL04Vehicle ICC13-7 Xenograft
SA333663SUB13746p4_SPL02Vehicle ICC13-7 Xenograft
Showing results 1 to 6 of 6
  logo